**A REVIEW ON - MUCORMYCOSIS**

**Pratik B Shinde\*¹, Miss. Ashwini A Wakade\*², Dr. Megha T Salve\*³**

**\*¹,²,³ Department of Bachelor In Pharmacy Shivajirao Pawar Collage of Pharmacy,**

**Pachegaon, Newasa, Ahamadnagar, India**

**Corresponding Author :- Pratik Bharat Shinde**

**ABSTRACT**

**Mucormycosis is a challenging infection to manage because of the lack of available diagnostic and therapeutic options.After aspergillosis and candidiasis, mucormycosis is the third most invasive fungal illness. Fungi that produce zygomycosis are to blame. Rhizopus is the primary species responsible for mucormycosis. Every year, there are roughly 1.7 instances of mucormycosis for every 1,000,000 people . Pain and redness around the eyes and nose, fever, headache, bloody vomiting, black fungal spot on the face, altered mental status, bloody mucus from the nose, local cheek bone pain, one-sided facial pain, numbness, toothache, blurred or double vision, etc. are some signs and symptoms of mucormycosis. The combination of many clinical data and the in vitro isolation of the fungus from clinical samples is necessary for the likely diagnosis of mucormycosis. Rapid identification, mitigating risk factors, surgical resection, debridement, and suitable antifungal treatment are all necessary for the treatment of mucormycosis . People who are diabetic or otherwise weakened, those who have cancer or neutropenia, and those who have just contracted COVID-19 In extreme circumstances, it may spread to the brain and be lethal.**

**KEYWORDS : Causes, COVID-19, Mucormycosis, Prevention, Symptoms, Treatment**

**INTRODUCTION**

**Mucormycosis is a life threatening Invasive Fungal Disease (IFD) Due to fungi belonging to Mucorales order from class zygomycetes which is post COVID-19 effect [1] Rarely detected, mucormycosis (zygomycosis) is a dangerous and potentially fatal fungal infection. Since mucormycosis is primarily caused by a fungal infection, but it can be caused by a variety of fungi, many researchers refer to it as mucormycosis instead of zygomycosis.[2] People who come into contact with environmental fungal spores get affected with mucormycosis. When someone breathes in fungal spores from the air or surroundings, their lungs or sinuses become infected.[3] Hematologic malignancies, renal failure, or diabetes mellitus are the clinical manifestations typically associated with mucormycosis. Additionally, rhinocerebral, pulmonary, disseminated, cutaneous (especially burn wounds), and gastrointestinal mucormycosis are affected by this illness. The term ”mucormycosis” was first used by American doctor R.D. Baker. Another name for it is zygomycosis. It is characterized as a sneaky fungal infection brought on by zygomycotic and Mucorales species.[4]**

**HISTORY**

**The first instance of mucormycosis was documented by the German doctor Paltauf in 1885, and he named it mucormycosis. The prevalence of mucormycosis in immunocompromised people increased over the 1980s and 1990s.[5] According to a French study, the prevalence rate increased by 74% year. There have been reports of mucosal infections all throughout the world, and seasonal variations may be possible.[6]**

**PATHOPHYSIOLOGY**

**Since neutrophils are the host for these infections, those who have neutropenia or dysfunctional neutrophils are most vulnerable. Patients who are at the highest risk, such as those with leukemia and bone marrow transplants, frequently experience this clinically.Fungi grow into hyphae in host tissues before invading blood vessels because studies on Rhizopus rhizome revealed that the ketone bodies in these patients re-educate ketones to metabolize so they may survive in acidic environments. The result of this widespread vascular invasion may be tissue necrosis and vascular thrombosis.[10,11]**

**TYPES OF MUCORMYCOSIS**

**1. Rhinocerebral mucormycosis**

**2. Pulmonary mucormycosis**

**3. Disseminated mucormycosis**

**4. Gastrointestinal mucormycosis**

**5. Cutaneous mucormycosis**

**1.Rhinocerebral Mucormycosis**

**It is an uncommon infection of the brain, sinuses, nasal passages, and oral cavity. It is frequently observed in people with impaired immune systems. In patients or people with weakened immunity already. The fungus spreads quickly and violently, resulting in potentially fatal illness.[7]**

**2.Pulmonary Mucormycosis**

**These fungi invade the host’s lungs. This is frequently linked to those who have just received a transplant and those who have blood malignancy.**

**3. Disseminated mucormycosis**

**All immunocompetent patients who arrive with cutaneous ulcerations and eschars should have disseminated cutaneous mucormycosis taken into consideration as a differential diagnosis, especially those who have a history of voriconazole (VRC) use or hematologic malignancies.[8]**

**4. Gastrointestinal mucormycosis**

**Fungi of this species target the host’s gastrointestinal tract, and they affect children more often than adults. Premature and underweight neonates are most commonly affected. The author of this case study has determined that a high index of suspicion, diagnostic testing, and the timely start of antifungal and surgical therapy are necessary for the effective management of gastrointestinal mucormycosis. [9]**

**5. Cutaneous Mucormycosis**

**Happens when a fungus enters the body through a skin break (such as following burns, surgery, or other skin trauma). Among those with a healthy immune system, this is the most prevalent mucormycosis.**

**SYMPTOMS OF MUCORMYCOSIS**

**Mucormycosis, also known as black fungus, is a rare but serious fungal infection. Here are its symptoms:**

**\*Common Symptoms:\***

**1. Sinusitis (inflammation of the sinuses)**

**2. Facial pain or pressure**

**3. Headaches**

**4. Fever**

**5. Coughing or difficulty breathing**

**6. Chest pain or tightness**

**7. Skin lesions or ulcers**

**8. Swelling around the eyes or nose**

**9. Loss of vision or double vision**

**10. Mental status changes (confusion, disorientation)**

**\*Specific Symptoms by Location:\***

**\*Rhinocerebral Mucormycosis (most common):\***

**1. Nasal congestion or discharge**

**2. Eye pain or swelling**

**3. Vision changes**

**4. Facial numbness**

**5. Headaches**

**\*Pulmonary Mucormycosis:\***

**1. Coughing or difficulty breathing**

**2. Chest pain or tightness**

**3. Fever**

**4. Coughing up blood**

**\*Cutaneous Mucormycosis:\***

**1. Skin lesions or ulcers**

**2. Swelling or redness**

**3. Pain or tenderness**

**4. Discharge or pus**

**\*Gastrointestinal Mucormycosis:\***

**1. Abdominal pain**

**2. Nausea or vomiting**

**3. Diarrhea or bloody stools**

**4. Fever**

**\*Disseminated Mucormycosis (spread to multiple organs):\***

**1. Fever**

**2. Chills**

**3. Confusion or disorientation**

**4. Organ failure (renal, hepatic, or respiratory)**

**\*Warning Signs:\***

**1. Sudden vision loss**

**2. Severe headache**

**3. Confusion or altered mental status**

**4. Difficulty breathing**

**5. Severe abdominal pain**

**\*High-Risk Groups:\***

**1. Immunocompromised individuals (cancer, HIV/AIDS, organ transplant)**

**2. Diabetics**

**3. Patients with chronic kidney disease**

**4. Those taking corticosteroids or immunosuppressants**

**DIAGNOSIS**

**Mucormycosis is rather easy to diagnose when rhino-orbital and mucocutaneous involvement are present. However, it becomes more challenging to get samples and, consequently, a proper diagnosis when deep tissues are invaded (as in the case of pulmonary mucormycosis). An ante-mortem diagnosis can be made in less than 50% of individuals with lung symptoms of a haematological illness.[12] Because they could indicate colonization, wide, non-septate hyphae in culture or on slides should always be read carefully. The combination of symptoms consistent with histological invasion of tissues is therefore necessary for the clinical form to be confirmed . Imaging-based diagnosis is equally challenging. Simple radiography and computed tomography scans typically reveal sinus invasion, orbital displacement, and invasion of the surrounding bone structures in cases of rhino-orbital lesions.Magnetic resonance imaging is the preferred method when intracranial structures are impacted.**

**CONCLUSION**

**A growing number of immunocompromised patients are infected with mucormycosis. The current treatment for mucormycosis consists of lipid-based amphotericin plus either itraconazole, echinocandin, or both. Furthermore, there is currently compassionate-use posaconazole accessible, and research into its potential for combination therapy with a polyene, caspofungin, or both is warranted. In the future, new medication treatments could be found to supplement conventional antifungal treatments. In cases where the patient is unable to breathe due to a respiratory tract infection, the optimum course of treatment is “hyperbolic oxygen therapy” along with concurrent “amphotericin-B.”**

**REFERANCE**

**1.Brunet K, Rammaert B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. J Mycol Med. 2020; 30(3):101007**

**2. Herbrecht R, Letscher-Bru V, Bowden RA et al.Treatmentof 21 cases of invasive mucormycosis with Amphotericin colloidal dispersion.Eur J Clin Microbial Infect Dis2001;20:460–6**

**3.Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser., 1989; 47: 243–271**

**4. Kwon-Chung KJ. Taxonomy of fungi causing Mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives. Clinical Infectious Diseases, 2012; 54(suppl\_1): S8-15.**

**5.Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clinical Infectious Diseases, 2005; 41(5): 634-53**

**6.Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical Manifestations of mucormycosis. Clinical Infectious Diseases, 2012; 54(suppl\_1): S23-34.**

**7. Waldorf AR, Ruderman N, Diamond RD. Specificsusceptibility to mucormycosis inMurine diabetesand bronchoalveolar macrophage defense against Rhizopus. J. Clin.Invest., 1984; 74: 150 60.**

**8.Victoria S Humphrey, X. L. 2020-Fatal Disseminated Mucormycosis in a Hematological Immunocompromised Patient with ExtensiveVoriconazole Exposure: A Case Report and Review of The Literature. Case Report in Dermatological Medicine , 12 (3), 168-173.**

**9. Prabudh Goel. 2013-Gastrointestinal mucormycosis: A Success story and appraisal of concepts. Journal of Infection and Public Health , 58-61.**

**10. Lin E, Moua T, Limper AH. Pulmonary mucormycosis: clinical features and outcomes. Infection. 2017 Aug; 45(4):443-448**

**11. Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common Mycoses? Clin Microbial Infect. 2014 Jun; 20 Suppl 6:74-81**

**12. Maertens J, Demuynck H, Verbeken EK et al. Mucormycosis in allogeneic bone marrow transplant recipients:Report of five cases and review of the role of iron overload In the pathogenesis. Bone Marrow Transplant 1999; 24: 307–312**